Robert Chilton
Overview
Explore the profile of Robert Chilton including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
67
Citations
764
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Karamchand S, Chipamaunga T, Naidoo P, Naidoo K, Rambiritch V, Ho K, et al.
JMIR Res Protoc
. 2025 Mar;
14:e44027.
PMID: 40063943
Background: Chronic heart failure has high morbidity and mortality, with approximately half of the patients dying within 5 years of diagnosis. Recent additions to the armamentarium of anti-heart failure therapies...
2.
Ramirez A, Howes S, Chilton R
Diabetes Obes Metab
. 2025 Feb;
PMID: 39949188
Ketamine, a dissociative anaesthetic, has expanded its clinical use beyond anaesthesia to pain management and treatment-resistant depression. As an N-methyl-d-aspartate receptor antagonist, ketamine disrupts the excitatory neurotransmission via interaction with...
3.
Harfouch B, Garcia M, Tolan S, Mantha Y, Hammadah M, Chilton R, et al.
J Soc Cardiovasc Angiogr Interv
. 2024 Aug;
1(5):100409.
PMID: 39131474
No abstract available.
4.
Yasuda T, Deans K, Shankar A, Chilton R
Cardiovasc Endocrinol Metab
. 2024 Aug;
13(3):e0309.
PMID: 39130369
This review summarizes the role of NETosis, or the release of neutrophil extracellular traps (NETs), and its interplay with the gut microbiome in acute myocardial infarction (AMI) and heart failure....
5.
Harfouch B, Chilton R
Rev Cardiovasc Med
. 2024 Jul;
24(5):130.
PMID: 39076746
No abstract available.
6.
Chen X, Tripathy D, Chilton R, Hansis-Diarte A, Salehi M, Solis-Herrera C, et al.
Diabetes
. 2024 Mar;
73(6):896-902.
PMID: 38512770
Article Highlights:
7.
Chilton R, Iranpour E, Bloomgarden Z
J Diabetes
. 2024 Feb;
16(2):e13539.
PMID: 38403297
No abstract available.
8.
Kramer B, Hauske S, Chilton R, Mann J, Gullestad L, Fitchett D, et al.
J Diabetes Complications
. 2023 Aug;
37(9):108588.
PMID: 37633072
Aims: Evaluate changes in haemodynamic markers as mediators of cardiovascular (CV) and kidney benefits with empagliflozin. Methods: Post-hoc analysis of EMPA-REG OUTCOME in patients with type 2 diabetes (T2D) and...
9.
Cincotta A, Cersosimo E, Alatrach M, Ezrokhi M, Agyin C, Adams J, et al.
Int J Mol Sci
. 2022 Aug;
23(16).
PMID: 36012132
Bromocriptine-QR is a sympatholytic dopamine D2 agonist for the treatment of type 2 diabetes that has demonstrated rapid (within 1 year) substantial reductions in adverse cardiovascular events in this population...
10.
Nashawi M, Ahmed M, Amin T, Abualfoul M, Chilton R
World J Cardiol
. 2022 Jan;
13(12):676-694.
PMID: 35070111
The beneficial cardiorenal outcomes of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in patients with type 2 diabetes mellitus (T2DM) have been substantiated by multiple clinical trials, resulting in increased interest in...